IceCure Medical Ltd (ICCM) Latest Company News

Aug 24, 2026, 11:50 UTC
IceCure Medical entered into an exclusive distribution agreement with Scovas Medical for the distribution of its ProSense cryoablation systems in the Netherlands for breast cancer and interventional oncology.
Source:
- prnewswire.com
Aug 20, 2026, 12:10 UTC
IceCure Medical announced that the Institutional Review Board of West Cancer Center & Research Institute approved its post-marketing ChoICE Study for ProSense cryoablation in low-risk breast cancer treatment.
Source:
- prnewswire.com
Aug 12, 2026, 17:07 UTC
IceCure Medical Ltd held its Q2 2026 earnings call on August 12, 2026.
Source:
- seekingalpha.com
- finance.yahoo.com
Aug 12, 2026, 12:30 UTC
IceCure Medical reported its financial results for the first half of 2026, with revenue growing 45% year-over-year and an approximately 70% increase in its active installed base following FDA clearance.
Source:
- prnewswire.com
Aug 6, 2026, 12:05 UTC
IceCure Medical announced that Adventist Health Glendale has signed an agreement and received IRB approval to become the first clinical site able to enroll patients in its post-marketing ChoICE study for low-risk breast cancer cryoablation treatment.
Source:
- prnewswire.com
Aug 5, 2026, 12:30 UTC
IceCure Medical announced it will report its financial and operating results for the six months ended June 30, 2026 on August 12, 2026.
Source:
- prnewswire.com
Jul 27, 2026, 12:32 UTC
IceCure Medical announced the start of its post-marketing ChoICE study for ProSense cryoablation in low-risk breast cancer at the first U.S. clinical site, West Cancer Center & Research Institute.
Source:
- prnewswire.com
Jun 25, 2026, 12:12 UTC
IceCure Medical received notice from Nasdaq that it has regained compliance with the minimum bid price requirement after its share price closed at $1.00 or above for 10 consecutive business days.
Jun 17, 2026, 17:14 UTC
IceCure Medical entered into securities purchase agreements for a $5.5 million private placement of ordinary shares and warrants with a single healthcare focused institutional investor.
Source:
- prnewswire.com
Jun 17, 2026, 16:45 UTC
IceCure Medical Ltd. reported a 70% increase in its U.S. commercial install base for ProSense, its breast cancer cryoablation system.
Source:
- benzinga.com

ICCM

IceCure Medical entered into an exclusive distribution agreement with Scovas Medical for the distribution of its ProSense cryoablation systems in the Netherlands for breast cancer and interventional oncology.

IceCure Medical announced that the Institutional Review Board of West Cancer Center & Research Institute approved its post-marketing ChoICE Study for ProSense cryoablation in low-risk breast cancer treatment.

IceCure Medical Ltd held its Q2 2026 earnings call on August 12, 2026.

IceCure Medical reported its financial results for the first half of 2026, with revenue growing 45% year-over-year and an approximately 70% increase in its active installed base following FDA clearance.

IceCure Medical announced that Adventist Health Glendale has signed an agreement and received IRB approval to become the first clinical site able to enroll patients in its post-marketing ChoICE study for low-risk breast cancer cryoablation treatment.

IceCure Medical announced it will report its financial and operating results for the six months ended June 30, 2026 on August 12, 2026.

IceCure Medical announced the start of its post-marketing ChoICE study for ProSense cryoablation in low-risk breast cancer at the first U.S. clinical site, West Cancer Center & Research Institute.

IceCure Medical received notice from Nasdaq that it has regained compliance with the minimum bid price requirement after its share price closed at $1.00 or above for 10 consecutive business days.

IceCure Medical entered into securities purchase agreements for a $5.5 million private placement of ordinary shares and warrants with a single healthcare focused institutional investor.

IceCure Medical Ltd. reported a 70% increase in its U.S. commercial install base for ProSense, its breast cancer cryoablation system.